CD73:癌症免疫疗法的新靶点  

CD73: A New Target for Cancer Immunotherapy

作　　者：黄松 刘煜[1] 

机构地区：[1]中国药科大学生命科学与技术学院,江苏 南京

出　　处：《药物资讯》2022年第4期259-266,共8页Pharmacy Information

摘　　要：第一代免疫检查点抑制剂在癌症治疗领域获得前所未有的成功,也因此成为癌症免疫疗法的基石。为了弥补抑制剂存在的缺陷,寻找安全有效,且能与第一代抑制剂产生协同作用的靶点则成为目前的重点。对于实体瘤治疗中克服耐药性的关键在于逆转免疫抑制微环境,其中CD73是催化产生腺苷的限速酶,因此靶向CD73的抗体药物可能与第一代抑制剂联用具有协同作用。本文旨在对CD73的结构、功能、与肿瘤关系及已开发药物的研究进展进行综述。The first generation of immune checkpoint inhibitors has achieved unprecedented success in cancer therapy and thus becomes the cornerstone of cancer immunotherapy. In order to make up for the defects of inhibitors, it is important to find safe and effective targets that can have synergistic effects with first-generation inhibitors. The key to overcoming drug resistance in the treatment of solid tumors is to reverse the immunosuppressive microenvironment in which CD73 is a rate-limiting enzyme catalyzing adenosine production, so antibody drugs targeting CD73 may have synergistic effects in combination with first-generation inhibitors. In this review, we reviewed the structure, function, relationship with tumor, and the development of CD73.

关 键 词：癌症免疫疗法 CD73 药物联用 

分 类 号：R73[医药卫生—肿瘤]